about
Hib Vaccines: Past, Present, and Future PerspectivesExtraintestinal Pathogenic Escherichia coli, a Common Human Pathogen: Challenges for Vaccine Development and Progress in the FieldCell factories for insulin productionHigh-throughput recombinant protein expression in Escherichia coli: current status and future perspectivesOuter membrane vesicles displaying engineered glycotopes elicit protective antibodiesExploitation of bacterial N-linked glycosylation to develop a novel recombinant glycoconjugate vaccine against Francisella tularensis.Synthetic Microbial Ecology: Engineering Habitats for Modular Consortia.Production of a recombinant vaccine candidate against Burkholderia pseudomallei exploiting the bacterial N-glycosylation machinery.Glycoconjugate vaccine containing Escherichia coli O157:H7 O-antigen linked with maltose-binding protein elicits humoral and cellular responses.Characterization of the structurally diverse N-linked glycans of Campylobacter species.An engineered eukaryotic protein glycosylation pathway in Escherichia coli.The sweet tooth of bacteria: common themes in bacterial glycoconjugates.Production of gamma-aminobutyric acid by Lactobacillus brevis NCL912 using fed-batch fermentationStructural insights from random mutagenesis of Campylobacter jejuni oligosaccharyltransferase PglB.Optimizing Escherichia coli as a protein expression platform to produce Mycobacterium tuberculosis immunogenic proteinsAntibodies to Staphylococcus aureus serotype 8 capsular polysaccharide react with and protect against serotype 5 and 8 isolatesInverse metabolic engineering to improve Escherichia coli as an N-glycosylation host.Glycoarrays with engineered phages displaying structurally diverse oligosaccharides enable high-throughput detection of glycan-protein interactionsStrain engineering for improved expression of recombinant proteins in bacteriaCombination vaccines against diarrheal diseases.The sweet branch of metabolic engineering: cherry-picking the low-hanging sugary fruitsHijacking bacterial glycosylation for the production of glycoconjugates, from vaccines to humanised glycoproteinsBiosynthesis of Conjugate Vaccines Using an O-Linked Glycosylation System.Chicken Anti-Campylobacter Vaccine - Comparison of Various Carriers and Routes of Immunization.Progress and pitfalls in Shigella vaccine research.Production of human blood group B antigen epitope conjugated protein in Escherichia coli and utilization of the adsorption blood group B antibody.Immunization with Outer Membrane Vesicles Displaying Designer Glycotopes Yields Class-Switched, Glycan-Specific Antibodies.Prevention of Staphylococcus aureus infections by glycoprotein vaccines synthesized in Escherichia coli.Glycoconjugate vaccines.Bacterial protein N-glycosylation: new perspectives and applications.Glycans-by-design: engineering bacteria for the biosynthesis of complex glycans and glycoconjugates.Expanding the landscape of recombinant protein production in Escherichia coli.Increased efficiency of Campylobacter jejuni N-oligosaccharyltransferase PglB by structure-guided engineering.Functional analysis of N-linking oligosaccharyl transferase enzymes encoded by deep-sea vent proteobacteria.Implications of plant glycans in the development of innovative vaccines.Therapies in early development for the treatment of urinary tract inflammation.O-antigen polymerase adopts a distributive mechanism for lipopolysaccharide biosynthesis.Carbohydrates as T-cell antigens with implications in health and disease.Bacteria like sharing their sweets.Engineering, conjugation, and immunogenicity assessment of Escherichia coli O121 O antigen for its potential use as a typhoid vaccine component.
P2860
Q26767144-61BFB92D-85A9-4A5A-8EC7-EE8320AC4504Q26786281-75975572-BE04-42C5-80B9-2AC728A9FE92Q27000550-6EDE49D7-9FD9-4E5C-96B5-66D8AA7A3C5EQ28066811-2C717CA5-DC47-4928-8208-4C1EFA33FBD3Q28831290-3D7611CA-086A-4200-8935-EE382530F1C7Q30559887-4445169F-882C-43DE-A67C-45B7B91C8F61Q33804367-62BFC56D-35E2-4F35-930A-3D18EA52A988Q33965527-517A35C5-CDF2-47CD-B102-6734860C71ABQ34066431-8CA42989-0D45-4EF7-A532-54AC2BDCE18BQ34184302-4D8A514C-4AC5-41D7-9B33-AFD392947F52Q34263550-E42B9187-CD1B-40B6-9DA8-CE485FDFFB89Q34297837-E60116CF-8B01-471B-865F-F9EC12C6BF43Q34375326-4D5CC02E-8DA4-4064-B6AE-CC8A79BC6508Q34420313-1C9D8ED3-2A74-473F-A04E-4C3C503B868CQ34477659-433E1E73-DBC7-4F16-ADF1-995B96A5BDE4Q34595644-D1292854-A36D-4294-9CFC-9C697108DE8BQ34660107-6B486EFA-98B0-4F7F-B183-B66297BA3B7EQ35039981-82EE92E7-CB0A-4C42-8C32-AA52F73F2A31Q35061014-CE988695-F0BE-4980-B35B-4C6CDB9810C0Q35896237-CD145AF8-3B21-4F89-A40B-2DDB3429BC35Q36361549-04F092CC-D490-4B57-BA5F-1344FAAC1153Q36496166-A62FDB35-5113-4DE9-96B6-5ECE8A099B41Q36849935-43D1CAE7-18BA-4B2A-9763-5E44C106CB52Q36915598-57538243-8E25-4A74-8C78-A8A85CA5E95AQ37105553-37D35F7A-7B8B-4D3C-AA0C-C0D42B0654A1Q37170056-5650FF02-C2EC-42AA-8E09-2D35D913D34AQ37425396-CBC1E12F-B80D-4B05-A952-60192DE0E903Q37719754-04542993-CD24-4786-BEBF-320DC5F2725EQ38044755-58187784-7DE4-4E92-87B1-8D560FBA3821Q38074949-95B96824-1FC9-4433-A1BD-CDF3738A2404Q38086151-D0338417-2BA0-498E-9441-5C65B30ACF9FQ38156334-3A72F0B1-2A20-4604-AE4B-0CE7904E584CQ38300058-286A3E36-4C2B-4FC5-B1AA-45934E3B712DQ38627991-F2298FA0-25A3-486B-892E-67D072C4EF87Q38738762-60EDCF20-BFFB-4D77-9505-E75505039A0AQ38757968-1BC806CF-525B-4C39-9B24-81E9E79CC3E9Q38794437-D50746BE-B15A-42CE-8299-B2017D8B9CD8Q38847198-E7F56384-FCAB-4ADE-A594-79496F215A4FQ38957342-08F218D8-16EC-4B94-86C8-DA0C5DA50474Q40271765-F4ACBCE5-B50F-42B4-91A5-7424EE44D87F
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականին հրատարակուած գիտական յօդուած
@hyw
2010 թվականին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Production of glycoprotein vaccines in Escherichia coli
@ast
Production of glycoprotein vaccines in Escherichia coli
@en
Production of glycoprotein vaccines in Escherichia coli
@nl
type
label
Production of glycoprotein vaccines in Escherichia coli
@ast
Production of glycoprotein vaccines in Escherichia coli
@en
Production of glycoprotein vaccines in Escherichia coli
@nl
prefLabel
Production of glycoprotein vaccines in Escherichia coli
@ast
Production of glycoprotein vaccines in Escherichia coli
@en
Production of glycoprotein vaccines in Escherichia coli
@nl
P2093
P2860
P3181
P356
P1476
Production of glycoprotein vaccines in Escherichia coli
@en
P2093
Cyril Tanner
Julian Ihssen
Linda Thöny-Meyer
Michael Kowarik
Michael Wacker
Sandro Dilettoso
P2860
P2888
P3181
P356
10.1186/1475-2859-9-61
P407
P577
2010-01-01T00:00:00Z
P5875
P6179
1015640506